I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Toxicology to Drive Growth of Expanding Toxicology Business
August 11 2020 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the
“Company”, “We” or “Our”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, announced today that I.M. (Gina) Grossi, Ph.D., has
joined the Company as Vice President, Toxicology, effective August
10, 2020. Dr. Grossi joins as the Company continues to invest in
people and facilities to support the growing demand for Inotiv
services.
Inotiv's philosophy, "Expect More," reflects a
broadly capable, right-sized CRO with a strong commitment to
client-focused service. Dr. Grossi's track record of successfully
managing a range of research activities and related financials,
coupled with her background in developing and cultivating client
relationships, is expected to blend seamlessly with the Company's
vision, mission and culture. Dr. Grossi will be responsible for
driving the further growth of Inotiv's Evansville, Indiana,
facility—a site that has seen a recent state-of-the-art expansion
and significant upgrades to the facility.
"I couldn't be more pleased to welcome Dr.
Grossi to the Inotiv team," said Philip Downing, the Company’s Sr.
Vice President, Nonclinical Services. "Dr. Grossi is an
accomplished industry leader with a history of success fueled by
establishing policies and directing initiatives to facilitate
managed growth of laboratory operations. With Dr. Grossi's
significant experience and leadership in designing and managing
preclinical development projects supporting INDs, nonclinical and
clinical development programs, she is a great fit to guide and
elevate our evolving operations and service offerings, and to
inspire our teams to continuously innovate and deliver value and a
superlative experience to our clients. I look forward to seeing the
positive impact she will have on our organization."
Prior to joining Inotiv, Dr. Grossi provided
independent consulting services for laboratory animal facility
operations, and held scientific leadership positions with RTI
Health Solutions, RTI International, Battelle Memorial Institute,
Liberty Research, Inc., and most recently, Chimerix, Inc., as
Director of Toxicology. Dr. Grossi holds a B.S. in
Biology/Chemistry from Central Michigan University, an M.B.A.
certification in Business Management from The Ohio State
University, and a Ph.D. in Cancer Biology from Wayne State
University School of Medicine in Detroit, Michigan. Dr. Grossi is a
member of the American College of Toxicology (ACT), the Society of
Toxicology (SOT), the North Carolina Chapter of the Society of
Toxicology (NCSOT) and the American Society for Microbiology
(ASM).
“I am delighted to join the Inotiv team and am
honored to be part of its broad spectrum of scientific expertise in
drug development,” said Dr. Grossi. "It is invigorating to be part
of a growing company that is responsive to evolving industry
demands and supports an efficient progression of client development
goals. I look forward to joining our stakeholders in doing things
that matter."
About the Company
Bioanalytical Systems, Inc., operating as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more
information about the Company.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the
successful closing, integration and business and financial impact
thereof, the impact of COVID-19 on the economy, demand for our
services and products and our operations, including the measures
taken by governmental authorities to address the pandemic, which
may precipitate or exacerbate other risks and/or uncertainties and
various other market and operating risks, including those detailed
in the Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact:Beth A. TaylorChief Financial
OfficerPhone: 765.497.8381btaylor@inotivco.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024